Antibody injections, treatment - a leading candidate for COVID19 Coronavirus cure
The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly's experimental treatment known as LY-CoV555, which is being developed...
The monoclonal antibody was identified from a blood sample taken from one of the first U.S. patients who recovered from Covid-19.
The ACTIV-3 trial is one of several ongoing trials that are part of an NIH program to accelerate the development of vaccine treatments.
Hospitals need to find space and staff to administer the drug at a time when there’s hardly enough of either to treat those who are sick.
Injections of antibodies might prevent mild COVID-19 from becoming severe, but the treatments are expensive and difficult to make.
Create
Sign in to save articles, videos, notes, and other finds.